Fig. 2: Schematic representation of Nano-antimicrobial based clinical trials. | npj Antimicrobials and Resistance

Fig. 2: Schematic representation of Nano-antimicrobial based clinical trials.

From: An Australian perspective on clinical, economic and regulatory considerations in emerging nanoparticle therapies for infections

Fig. 2

a Treatment for various bacterial infections. Wherein, BOS Bronchiolitis Obliterans Syndrome, PAI Pseudomonas aeruginosa Infection, URTI Upper respiratory tract infection, and HAI healthcare-associated infections (Nosocomial). b Treatment for various Fungal and Parasitic infections. Wherein, DHCI Disseminated Histoplasma Capsulatum Infection. Figure prepared using Ayoa Ultimate software.

Back to article page